Do GLP-1s cause cancer? The thyroid warning and what the studies show
Reviewed 21 sourcesPublished by PepVault
The thyroid warning on Ozempic, Wegovy, Mounjaro and Zepbound comes from rats. What human studies, FDA and EMA found on thyroid, pancreatic and other cancers.

- Last reviewed
- Sources
- 21
- Questions
- 8
- Compounds
- 3
The short answer
No study has shown that Ozempic, Wegovy, Mounjaro or Zepbound cause cancer in people. Their boxed thyroid warning comes from rats and mice, and the labels rule all four out for anyone with a personal or family history of medullary thyroid cancer or MEN 2. Human studies split on thyroid cancer, and a 48-trial review found little or no effect on thyroid, pancreatic, breast or kidney cancer.
- The boxed warning on all four labels comes from thyroid tumors in mice and rats; its relevance to people has not been determined.
- Health-record studies split on thyroid cancer; the US rise came in the first year, which its authors said may have been due to earlier detection.
- Pancreatic cancer did not rise in an Israeli 7-year study, in six semaglutide trials or in a 48-trial review.
- A personal or family history of medullary thyroid cancer, or MEN 2, rules all four drugs out; any other history is the prescriber's call.
Evidence: The warning rests on 2-year rodent studies; the human evidence is health-record studies of up to 2.6 million people and pooled randomized trials, mostly 1 to 5 years long and not designed to count cancer.

What does the cancer warning on Ozempic, Wegovy, Mounjaro and Zepbound say?
All four labels open with the same boxed warning (pepvault.app/glossary/boxed-warning), the FDA's strongest label warning: "Risk of thyroid C-cell tumors". C-cells are the thyroid cells that make the hormone calcitonin, and the cancer they can form is medullary thyroid carcinoma (MTC), a rare thyroid cancer. Ozempic's words: "In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans"1. Wegovy says the same of semaglutide2; Mounjaro and Zepbound say it of tirzepatide in rats34.
| Label (current version) | Animals with tumors | What the 2-year studies found | Who must not use it |
|---|---|---|---|
| Ozempic, semaglutide (June 1, 2026) | Mice and rats | More C-cell adenomas (benign tumors) in both sexes of both species; more carcinomas in male rats1 | A personal or family history of MTC, or MEN 21 |
| Wegovy, semaglutide (June 18, 2026) | Mice and rats | The same: adenomas at every dose in both species; carcinomas in male rats, at up to 0.7 times the human exposure2 | The same2 |
| Mounjaro, tirzepatide (August 27, 2026) | Rats, both sexes | Adenomas and carcinomas combined rose at every dose, 0.1 to 1 times the human exposure; none in a 6-month study of transgenic mice3 | The same3 |
| Zepbound, tirzepatide (August 28, 2026) | Rats, both sexes | The same as Mounjaro4 | The same4 |
MEN 2 (multiple endocrine neoplasia type 2) is an inherited condition that makes MTC likely, which is why it is a contraindication (pepvault.app/glossary/contraindication), a reason not to use the drug at all1234. The semaglutide labels add that MTC cases have been reported in people on liraglutide, an older GLP-1, and that those reports are "insufficient to establish or exclude a causal relationship"12. The brand pages hold each label in full: pepvault.app/drugs/ozempic, pepvault.app/drugs/wegovy, pepvault.app/drugs/mounjaro and pepvault.app/drugs/zepbound.

Why do rats get thyroid tumors on GLP-1 drugs?
Rat C-cells carry plenty of the GLP-1 receptor, the switch these drugs press; human and monkey C-cells carry little. Novo Nordisk scientists showed in 2010 that the drugs made rodent C-cells release calcitonin and multiply, while 20 months of liraglutide at over 60 times the human exposure caused no C-cell growth in monkeys5. The full rodent story is at pepvault.app/guides/retatrutide-and-cancer.
Species note: the tumors are a finding in mice and rats. Every label says their relevance to people "has not been determined"1234.
Do GLP-1s cause thyroid cancer in people?
Seven major studies split, and the absolute numbers are small either way. In the table, a result above 1 means more thyroid cancer on a GLP-1 and below 1 means less; when the range in brackets (the confidence interval, pepvault.app/glossary/confidence-interval) crosses 1, the study found no clear difference. The first four are observational studies (pepvault.app/glossary/observational-study) of health records; the last three pool randomized trials.
| Study | Who | Thyroid cancer result (95% range) |
|---|---|---|
| France, 20236 | 2,562 people with thyroid cancer and 45,184 matched controls, all with type 2 diabetes | 1 to 3 years of use: 1.58 (1.27 to 1.95); MTC 1.78 (1.04 to 3.05) |
| Denmark, Norway and Sweden, 20247 | 145,410 GLP-1 users against 291,667 users of DPP-4 inhibitors, another diabetes drug; mean 3.9 years | 0.93 (0.66 to 1.31); MTC 1.19 (0.37 to 3.86) |
| Six countries, 20258 | 98,147 GLP-1 users against 2,488,303 DPP-4 inhibitor users; median 1.8 to 3.0 years | 0.81 (0.59 to 1.12); no rise with higher total dose |
| United States, 20259 | 351,913 adults with type 2 diabetes, 41,112 of them starting a GLP-1 | Overall 1.24 (0.88 to 1.76); first year 1.85 (1.11 to 3.08) |
| 64 trials, 202410 | Randomized trials lasting 52 weeks or more | 1.52 (1.01 to 2.29); MTC 1.44 (0.23 to 9.16) |
| 50 trials, 202521 | Diabetes and obesity trials lasting 52 weeks or more | 1.55 (1.05 to 2.27), clearer in the longer trials |
| 48 trials, 202611 | 94,245 people in placebo-controlled trials, semaglutide and tirzepatide included | 1.37 (0.82 to 2.31): 1 fewer to 9 more cases per 10,000 treated |
In the US study, thyroid cancer was diagnosed in 0.17% of people who started a GLP-1, against 0.17% to 0.23% on three other diabetes drugs, and the rise was clear only within the first year after starting, which the authors said "may have been due to enhanced early detection"9: a new drug brings more check-ups, and more check-ups can find small thyroid cancers that were already there. The Scandinavian rates: 1.33 cases per 10,000 person-years on a GLP-1, 1.46 on the comparison drug7.
The 2024 trial pool's rise rests on a single case (a fragility index of 1): one extra thyroid cancer for every 1,349 people treated for five years10. The 2025 pool of 50 trials found a similar rise, clearer in trials of two years or more21. The 2026 review, which kept only placebo-controlled trials and is the largest so far, rated the evidence moderate and found little or no effect11. For MTC itself the cases are few: the French study found a rise, and the Scandinavian study and the 2024 trial pool found no clear difference6710.
If you notice anything new while on a GLP-1, PepVault's side-effect log keeps each symptom with its date and severity, next to the doses you logged. Log it in PepVault
What did the FDA and EMA conclude?
- EMA, thyroid, October 2023. After the French study, the EMA's safety committee (PRAC) reviewed the published studies and the makers' data, and concluded that "the available evidence does not support a causal association" between the five GLP-1 drugs it reviewed (semaglutide among them, tirzepatide not) and thyroid cancer. It saw no reason to change the product information12.
- EMA, pancreas, July 2013. After a study of a small number of pancreas samples from organ donors, the EMA's medicines committee found that trial data "do not indicate an increased risk" of pancreatic cancer, while the number of cases was too small for final conclusions13.
- FDA and EMA, February 2014. The two agencies' joint review of pancreatic safety for incretin drugs (pepvault.app/glossary/incretin), the family GLP-1s belong to, appeared in the New England Journal of Medicine14.
- FDA, as of November 20, 2026. The boxed thyroid warning stays on all four US labels, in their 2026 versions1234, and a US registry run by Novo Nordisk with Eli Lilly and AstraZeneca counts new adult MTC cases each year to catch any rise tied to GLP-1 drugs; it is planned to run to 203915.
Do GLP-1s cause pancreatic cancer?
The large studies have found no rise in pancreatic cancer on a GLP-1. An Israeli study followed 543,595 adults with diabetes for up to seven years and found no rise against basal insulin: 0.52 (0.19 to 1.41) from the fifth year after starting16. Six placebo-controlled semaglutide trials with 38,057 people counted 32 pancreatic cancers on the drug and 41 on placebo, an odds ratio of 0.78 (0.49 to 1.24)17. Across 48 trials of GLP-1 and dual agonists, the result was 0.84 (0.53 to 1.35)11.
The pancreas warning that is on the labels is for pancreatitis, an inflammation of the pancreas, which is rare; it is covered at pepvault.app/guides/are-glp-1s-safe-long-term, with the other long-term risks.
Can a GLP-1 lower the risk of other cancers?
Excess body fat causes at least 13 cancers, the WHO's cancer agency (IARC) concluded in 2016 after more than a thousand studies: cancers of the esophagus, upper stomach, colon and rectum, liver, gallbladder, pancreas, breast after menopause, womb, ovary, kidney and thyroid, plus meningioma and multiple myeloma18. Its group wrote that evidence for intentional weight loss lowering cancer "in humans remains to be established"18.
| Study | Who | What it found |
|---|---|---|
| US health records, 202419 | 1,651,452 adults with type 2 diabetes | Against insulin: lower risk of 10 of 13 obesity-linked cancers, pancreatic 0.41 and colorectal 0.54 among them. Against metformin: none lower, kidney cancer higher, 1.54 (1.27 to 1.87) |
| Florida health records, 202520 | 86,632 adults with obesity, half on a GLP-1 | 14 cancers at 13.6 against 16.4 per 1,000 person-years, 0.83 (0.76 to 0.91); womb 0.75, ovary 0.53, meningioma 0.69; kidney 1.38 (0.99 to 1.93) |
| 50 trials, 202521 | Diabetes and obesity trials of 52 weeks or more | Overall cancer 1.05 (0.98 to 1.13); fewer uterine cancers in the obesity trials |
| 48 trials, 202611 | 94,245 people, placebo-controlled | Little or no effect on breast and kidney cancer (moderate certainty) and on most others (low certainty); stomach cancer very uncertain |
The record studies mostly point to fewer cancers, the trials to no change; the trials are short and were not built to count cancer11. The 2025 trial pool also found a rise in colorectal cancer in the shorter trials only, which its authors suggest may come from more bowel tests prompted by the drugs' stomach side effects21. No GLP-1 is approved to prevent cancer.
Can you take a GLP-1 with a family history of thyroid cancer?
The labels draw one line: a personal or family history of medullary thyroid carcinoma, or MEN 2, rules all four drugs out1234. They name no other cancer history. The more common thyroid cancers, such as papillary, are not in the contraindication, and the labels say routine calcitonin tests or thyroid ultrasounds are "of uncertain value" for catching MTC early and can lead to unnecessary procedures12. Whether a GLP-1 suits someone with a thyroid nodule, a past cancer or a relative with an unnamed thyroid cancer is the prescriber's decision, made with the label and your history.
When to get help The labels name the signs to report: a lump or swelling in the neck, trouble swallowing, shortness of breath, or hoarseness that does not go away; any of these is a reason to see your doctor13.
PepVault's doctor's report puts your doses, consistency, weight and logged side effects on one page to bring to that appointment. Track your weight in PepVault
What is still unknown about GLP-1s and cancer?
- Decades of use. Most studies follow people for 2 to 5 years, and cancers can take longer7811. The MTC registry is planned to run to 203915.
- The kidney signal. One record study found more kidney cancer against metformin, though less against insulin, and another a borderline rise against non-users1920; the 2026 trial review found no clear difference11.
- The newest drugs. Retatrutide, still in trials, has no label; its cancer data are at pepvault.app/guides/retatrutide-and-cancer.
Sources
- OZEMPIC (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, version 20, effective June 1, 2026 (published June 10, 2026): boxed warning, 4, 5.1, 13.1. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) injection and tablets, prescribing information. Novo Nordisk. DailyMed, version 19, effective June 18, 2026 (published June 30, 2026): boxed warning, 4, 5.1, 13.1. dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, version 40, effective August 27, 2026 (published September 2, 2026): boxed warning, 4, 5.1, 13.1. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, version 40, effective August 28, 2026 (published September 2, 2026): boxed warning, 4, 5.1, 13.1. dailymed.nlm.nih.gov
- Bjerre Knudsen L et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010. PubMed 20203154
- Bezin J et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023. PubMed 36356111
- Pasternak B et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024. PubMed 38683947
- Baxter SM et al. Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study. Thyroid. 2025. PubMed 39772758
- Brito JP et al. GLP-1RA use and thyroid cancer risk. JAMA Otolaryngol Head Neck Surg. 2025. PubMed 39847346
- Silverii GA et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024. PubMed 38018310
- Ko A et al. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis. Ann Intern Med. 2026. PubMed 41359966
- European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023: GLP-1 receptor agonists, available evidence not supporting link with thyroid cancer. Published October 27, 2023. ema.europa.eu
- European Medicines Agency. Investigation into GLP-1-based diabetes therapies concluded. July 26, 2013. ema.europa.eu
- Egan AG et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014. PubMed 24571751
- ClinicalTrials.gov NCT01511393. An active surveillance program for cases of medullary thyroid carcinoma (MTC). Sponsor Novo Nordisk, with AstraZeneca and Eli Lilly; estimated completion December 2039. clinicaltrials.gov
- Dankner R et al. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open. 2024. PubMed 38175642
- Chiang CH et al. Semaglutide and risk of pancreatic cancer: a meta-analysis of randomised trials. Diabetes Obes Metab. 2026. PubMed 42297743
- Lauby-Secretan B et al.; IARC Handbook Working Group. Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med. 2016. PubMed 27557308
- Wang L et al. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024. PubMed 38967919
- Dai H et al. GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncol. 2025. PubMed 40839273
- Silverii GA et al. GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2025. PubMed 40437949
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.